… might improve the prognosis of patients with moderate to severe COVID-19 (ie, patients …
the effect of anakinra treatment on mortality in patients admitted to hospital with COVID-19. …

… COVID-19 and hyperinflammation. An updated systematic review and meta-analysis regarding
the impact of anakinra on … of anakinra in the treatment of selected patients with COVID-19. …

… in COVID-19 due to its great safety profile. Considering the beneficial effects of anakinra in
… aimed to review the literature to define which COVID-19 patients benefit most from anakinra. …

… Patients with COVID-19 pneumonia have an … anakinra, a recombinant human IL-1 receptor
antagonist, could improve outcomes in patients in hospital with mild-to-moderate COVID-19 …

… among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients
who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of …

… In the present study, the effects of anakinra in critically ill COVID-19 patients with clinical
features of MAS/hyperinflammation were compared to critically ill COVID-19 patients that did not …

… Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen
activator receptor (suPAR). However, the role of Anakinra in COVID-19 … effects of Anakinra …

… the effects of the interleukin1 receptor antag onist anakinra in patients with severe COVID19
with … a group of patients with severe COVID19 treated with anakinra plus standard of care (…

… therapies in the management of COVID-19. We have established that evidence for the
efficacy of anakinra, siltuximab or sarilumab in COVID-19 is currently insufficient and adequately …

… Therefore, it would be interesting to learn if the effects of anakinra observed in the study
by … for using anakinra in the treatment of patients who are critically ill with COVID-19 and …